17:I[66739,["/_next/static/chunks/0.3dg.jzl0xwf.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/0skdv12y78fnh.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/10dnvbzcepzg2.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/0w-9dtq49e_fk.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/1331nw5i_3lcb.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/053zyoym-_i67.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V"],"default"] 19:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V"],"IconMark"] 18:T4e0,

In this episode of The Top Line, Fierce’s Chris Hayden speaks with Foresight Diagnostics co-founders Dr. Jake Chabon and Dr. Max Diehn about how their company is delivering the next generation of minimal residual disease (MRD) detection in cancer care.

Born from research at Stanford University, Foresight’s PhasED-Seq technology delivers ultra-sensitive detection—down to parts per ten million—enabling clinicians to identify microscopic traces of cancer that traditional imaging misses. The discussion explores how Foresight’s MRD platform, CLARITY, can have the ability to support more confident decision-making, from determining curative success in early-stage cancers to guiding consolidation treatment in lymphoma.

Chabon and Diehn highlight the company’s biopharma collaborations, clinical trial integration, and evidence-driven approach to guideline inclusion. They also look ahead to a future where MRD testing becomes central to oncology surveillance, accelerating therapy approvals and complementing genomic and digital pathology tools to advance precision medicine.

See omnystudio.com/listener for privacy information.

Inside Foresight’s mission to redefine cancer monitoring (Sponsored)

The Top Line

Inside Foresight’s mission to redefine cancer monitoring (Sponsored)